Key result
Sacubitril/valsartan reduces the risks of all-cause mortality, cardiovascular mortality, sudden cardiac death, and hospitalizations in patients with HFrEF.
Why the study?
Patients with HFrEF remain at high risk of sudden cardiac death, indicating that HFrEF treatment requires further improvement.
Does sacubitril/valsartan reduce the risk of sudden cardiac death in patients with HFrEF?
Does sacubitril/valsartan reduce the risk of sudden cardiac death in patients with HFrEF?
Sacubitril/valsartan is associated with a reduced risk of sudden cardiac death and improved overall outcomes in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
May support sacubitril/valsartan to lower sudden cardiac death in HFrEF; leaves open need for prospective confirmation.
Patients with heart failure (HF) with reduced left ventricle ejection fraction (HFrEF) are at high risk of sudden cardiac death (SCD). Therefore HFrEF treatment requires further improvement, which may be accomplished with the use of sacubitril/valsartan. Sacubitril/valsartan reduce the risks of allcause mortality, cardiovascular mortality, SCD, HF mortality, HF and all-cause hospitalizations, as well as symptoms of HF. It was also shown that use of sacubitril/valsartan may be associated with a reduced number of adequate and inadequate
No takes yet. Share an insight, caveat, or question.
Ozierański et al. (2018) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan was evaluated. Sacubitril/valsartan reduces the risks of all-cause mortality, cardiovascular mortality, sudden cardiac death, and hospitalizations in patients with HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: